Table 2.
Multivariable analysis on baseline plasma NfL levels with cognitive and motor outcomes in PD patients
| Group | MDS-UPDRS Part III (Motor)a | H&Y | MoCA |
|---|---|---|---|
| βb (95% CI) | β (95% CI) | β (95% CI) | |
| Total PD | −0.567 (−4.775, 3.642) | − 0.029 (− 0.214, 0.157) | −0.455 (− 1.995, 1.086) |
| TD | −6.815 (− 14.036, 0.407) | − 0.188 (− 0.498, 0.121) | 1.437 (− 0.757, 3.631) |
| PIGD | 10.687** (3.325, 18.050) | 0.292 (− 0.021, 0.605) | −3.168* (− 5.954, − 0.382) |
Abbreviations: PD Parkinson’s Disease; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; H&Y stage Hoehn and Yahr stage; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MoCA Montreal Cognitive Assessment; CI Confidence Interval; NfL, Neurofilament light chain protein
a MDS-UPDRS Part III (Motor) scores, H&Y stages and MoCA scores of PD patients are the outcome variables
b Beta coefficient (and 95% CI) of Ln-NfL level; Multivariable linear regression adjusted for age, sex and disease duration
* P < 0.05, ** P < 0.01